HeartBeam Inc.'s VALID-ECG Study Confirms High Diagnostic Accuracy of Synthesized 12-Lead ECG
TL;DR
HeartBeam's credit card-sized ECG device offers a competitive edge with 93.4% diagnostic agreement, positioning it for FDA clearance and U.S. market entry.
The VALID-ECG study methodically compared HeartBeam's synthesized 12-lead ECG with standard ECGs, achieving 93.4% diagnostic agreement in 198 patients.
HeartBeam's portable ECG technology enhances cardiac care accessibility, enabling accurate arrhythmia monitoring outside medical facilities for better patient outcomes.
Discover HeartBeam's breakthrough in cardiac care with a compact ECG device that matches standard ECGs' accuracy, revolutionizing heart health monitoring.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT) has announced a pivotal achievement in cardiac care technology with its VALID-ECG study results, demonstrating a 93.4% diagnostic agreement between its synthesized 12-lead ECG and standard ECGs for arrhythmia assessment. This breakthrough, presented by Dr. Thomas Deering of Piedmont Heart Institute at the Heart Rhythm Society's annual meeting, underscores the potential of HeartBeam's compact, patient-friendly device to revolutionize arrhythmia monitoring outside traditional medical settings.
The study, conducted across five U.S. clinical sites with 198 patients, compared ECG intervals and amplitudes between HeartBeam's synthesized output and standard ECGs. The findings not only validate the accuracy of HeartBeam's technology but also support its FDA submission for ECG synthesis software, filed in January 2025. CEO Robert Eno highlighted the importance of this development in enabling accurate, on-demand arrhythmia monitoring, which could significantly improve patient outcomes by facilitating early detection and intervention.
With FDA clearance on the horizon, HeartBeam has initiated an Early Access Program to optimize clinical workflows and gear up for its U.S. market debut. This advancement represents a critical leap towards making sophisticated cardiac care accessible anytime, anywhere, potentially reducing the burden on healthcare facilities and empowering patients with real-time heart health insights.
Curated from InvestorBrandNetwork (IBN)
